First in Class Drug AK03 for the Prophylaxis of Peritoneal Adhesions
Akesion GmbH develops the AK03 for the prophylaxis of postoperative peritoneal adhesions. Adhesions are a frequent and severe complication caused by local irritation, trauma and ischemia, occurring after more than 50% of abdominal surgeries. Adhesions are a major cause of female infertility, chronic pain, or life threatening bowel obstructions. Almost every third patient is readmitted with adhesion-related complications within ten years. This is associated with a significant health economic burden.
AK03 is a novel fibrinogenolytic enzyme which is designed for retention in the peritoneum. AK03 reduced adhesion formation in rats by more than 50% without systemic side effects. The liquid formulation allows for administration in laparotomy and laparoscopy.
Akesion GmbH is a project company coordinating strategic development. The next milestone is clinical proof of concept in human patients.
Phone: +49 176 81230027
Get in contact with German companies in 3 easy steps! With one single question you can reach all relevant German Pavilion exhibitors of your selected industrial branch.
Click here if you notice an image that violates copyright or privacy rights.